Skip to main content
SpringerLink
Log in
Book cover

Improving Outcomes for Breast Cancer Survivors pp 213–230Cite as

Prevention and Treatment of Cardiac Dysfunction in Breast Cancer Survivors

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((BCRF,volume 862))

Abstract

As recurrence free survival following a breast cancer diagnosis continues to improve, cardiovascular morbidity and mortality will assume greater importance in the breast cancer survivorship research agenda particularly for women receiving potentially cardiotoxic therapy. Development of (1) tools to readily identify pre-diagnostic risk factors for cardiac dysfunction, (2) well-tolerated prophylactic treatments to reduce the risk of cardiac injury, and (3) sensitive and affordable monitoring techniques which can identify subclinical toxicity prior to a drop in left ventricular ejection fraction are or should be focus areas of cardio-oncology research. Since weight as well as cardiorespiratory fitness generally decline after a breast cancer diagnosis, behavioral approaches which can improve energy balance and fitness are important to optimize cardiovascular health in all breast cancer survivors not just those undergoing cardiotoxic therapy. These goals are likely best achieved by partnerships between cardiologists, oncologists and internists such as those initiated with the formation of the International CardiOncology Society (ICOS) and the NCI Community Cardiotoxicity Task Force.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Barlow CE, Defina LF, Radford NB et al (2012) Cardiorespiratory fitness and long-term survival in “low-risk” adults. J Am Heart Assoc 1(4):e001354

    Article  PubMed Central  PubMed  Google Scholar 

  • Barry VW, Baruth M, Beets MW et al (2014) Fitness vs. fatness on all-cause mortality: a meta-analysis. Prog Cardiovasc Dis 56(4):382–390

    Article  PubMed  Google Scholar 

  • Baselga J, Cortés J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119

    Article  CAS  PubMed  Google Scholar 

  • Beauclair S, Formento P, Fischel JL et al (2007) Role of HER2Ille65VAL genetic polymorphism in tumorgenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 18:1335–1341

    Article  CAS  PubMed  Google Scholar 

  • Bellenger NG, Grothues F, Smith GC et al (2000) Quantification of right and left ventricular function by cardiovascular magnetic resonance. Herz 25:392–399

    Article  CAS  PubMed  Google Scholar 

  • Bersell K, Arab S, Haring B et al (2009) Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138:257–270

    Article  CAS  PubMed  Google Scholar 

  • Bird BR, Swain SM (2008) Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 14(1):14–24

    Article  CAS  PubMed  Google Scholar 

  • Bosch X, Esteve J, Sitges M et al (2011) Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail 17(8):643–648

    Article  PubMed  Google Scholar 

  • Bovelli D, Plataniotis G, Roila F (2010) Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Ann Oncol 21(Suppl 5):v277–v282

    Article  PubMed  Google Scholar 

  • Bowles EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293–1305

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Burnett D, Kluding P, Porter C et al (2013) Cardiorespiratory fitness in breast cancer survivors. Springerplus 2(1):68 (Epub 2013 Feb 25)

    Article  PubMed Central  PubMed  Google Scholar 

  • Cameron D, Brown J, Dent R et al (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14(10):933–942

    Article  CAS  PubMed  Google Scholar 

  • Cardinale D, Colombo A, Torrisi R et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910–3916

    Article  CAS  PubMed  Google Scholar 

  • Carver JR, Shapiro CL, Ng A et al (2007) American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25:3991–4008

    Article  CAS  PubMed  Google Scholar 

  • Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31(33):4222–4228

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chen J, Long JB, Hurria A et al (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60(24):2504–2512

    Article  CAS  PubMed  Google Scholar 

  • Cheng S, Larson MG, McCabe EL et al (2013) Age- and sex-based reference limits and clinical correlates of myocardial strain and synchrony: the Framingham heart study. Circ Cardiovasc Imaging 6(5):692–699

    Article  PubMed  Google Scholar 

  • Courneya KS, McKenzie DC, Mackey JR et al (2013) Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst 105(23):1821–1832

    Article  PubMed  Google Scholar 

  • Courneya KS, Segal RJ, McKenzie DC et al (2014) Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. Med Sci Sports Exerc Mar 46(9):1744–1751

    Article  CAS  Google Scholar 

  • Darby SC, Ewertz M, Hall P (2013) Ischemic heart disease after breast cancer radiotherapy. N Engl J Med 368(26):2527

    Article  CAS  PubMed  Google Scholar 

  • De Angelis A, Piegari E, Cappetta D et al (2010) Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121(2):276–292

    Article  PubMed Central  PubMed  Google Scholar 

  • de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 32(20):2159–2165

    Article  PubMed  Google Scholar 

  • De Keulenaer GW, Doggen K, Lemmens K (2010) The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106(1):35–46

    Article  PubMed  Google Scholar 

  • Deng S, Wojnowski L (2007) Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 7:129–134

    Article  CAS  PubMed  Google Scholar 

  • Dhaliwal SS, Welborn TA, Howat PA (2013) Recreational physical activity as an independent predictor of multivariable cardiovascular disease risk. PLoS ONE 8(12):e83435

    Article  PubMed Central  PubMed  Google Scholar 

  • Ewer MS, Glück S (2009) A woman’s heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 115(9):1813–1826

    Article  CAS  PubMed  Google Scholar 

  • Extra JM, Antoine EC, Vincent-Salomon A et al (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15(8):799–809

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ezaz G, Long JB, Gross CP et al (2014) Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3(1):e000472

    Article  PubMed Central  PubMed  Google Scholar 

  • Fairey AS, Courneya KS, Field CJ et al (2005) Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial. Brain Behav Immun 19(5):381–388

    Article  CAS  PubMed  Google Scholar 

  • Fallah-Rad N, Walker JR, Wassef A et al (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57:2263–2270

    Article  CAS  PubMed  Google Scholar 

  • Fedele C, Riccio G, Malara AE et al (2012) Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat 134(2):595–602

    Article  CAS  PubMed  Google Scholar 

  • George SM, Irwin ML, Smith AW et al (2011) Postdiagnosis diet quality, the combination of diet quality and recreational physical activity, and prognosis after early-stage breast cancer. Cancer Causes Control 22(4):589–598

    Article  PubMed Central  PubMed  Google Scholar 

  • Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial. Lancet Oncol 12(3):236–244

    Article  CAS  PubMed  Google Scholar 

  • Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028

    Article  CAS  PubMed  Google Scholar 

  • Hamilton DM, Haennel RG (2000) Validity and reliability of the 6-minute walk test in a cardiac rehabilitation population. J Cardiopulm Rehabil 20(3):156–164

    Article  CAS  PubMed  Google Scholar 

  • Hervent AS, De Keulenaer GW et al (2012) Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int J Mol Sci 13(10):12268–12286

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Irwin ML, Crumley D, McTiernan A et al (2003) Physical activity levels before and after a diagnosis of breast carcinoma: the health, eating, activity, and lifestyle (HEAL) study. Cancer 97:1746–1757

    Article  PubMed Central  PubMed  Google Scholar 

  • Irwin ML, McTiernan A, Manson JE et al (2011) Physical activity and survival in postmenopausal women with breast cancer: results from the women’s health initiative. Cancer Prev Res (Phila) 4(4):522–529

    Article  Google Scholar 

  • Jones LW, Haykowsky M, Peddle CJ et al (2007) Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev 16(5):1026–1031

    Article  CAS  PubMed  Google Scholar 

  • Jones LW, Courneya KS, Mackey JR et al (2012) Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol 30(20):2530–2537

    Article  PubMed Central  PubMed  Google Scholar 

  • Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258–2262

    Article  CAS  PubMed  Google Scholar 

  • Khouri MG, Hornsby WE, Risum N et al (2014) Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. Breast Cancer Res Treat 143(3):531–539

    Article  CAS  PubMed  Google Scholar 

  • Kodama S, Saito K, Tanaka S et al (2009) Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 301(19):2024–2035

    Article  CAS  PubMed  Google Scholar 

  • Kumar D, Kirshenbaum L, Li T et al (1999) Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Ann NY Acad Sci 874:156–168

    Article  CAS  PubMed  Google Scholar 

  • Ky B, Putt M, Sawaya H et al (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with Doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63(8):809–816

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lakoski SG, Barlow CE, Koelwyn GJ et al (2013) The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study. Breast Cancer Res Treat 138(3):909–916

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lee IM, Skerrett PJ (2001) Physical activity and all-cause mortality: what is the dose-response relation? Med Sci Sports Exerc 33(6 suppl):S459–S471

    Article  CAS  PubMed  Google Scholar 

  • Lenihan DJ (2012) Progression of heart failure from AHA/ACC stage A to stage B or even C: can we all agree we should try to prevent this from happening? J Am Coll Cardiol 60:2513–2514

    Article  PubMed  Google Scholar 

  • Lenihan DJ, Cardinale D, Cipolla CM (2010) The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis 53(2):88–93

    Article  PubMed  Google Scholar 

  • Lenihan DJ, Oliva S, Chow EJ et al (2013) Cardiac toxicity in cancer survivors. Cancer 119(Suppl 11):2131–2142

    Article  PubMed  Google Scholar 

  • Lotrionte M, Biondi-Zoccai G, Abbate A et al (2013) Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 112(12):1980–1984

    Article  CAS  PubMed  Google Scholar 

  • Mosca L, Benjamin EJ, Berra K et al (2012) Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 57(12):1404–1423

    Article  Google Scholar 

  • Naumann D, Rusius V, Margiotta C et al (2013) Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer. Anticancer Res 33(4):1717–1720

    CAS  PubMed  Google Scholar 

  • Onitilo AA, Engel JM, Stankowski RV et al (2012) High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat 134(1):291–298

    Article  CAS  PubMed  Google Scholar 

  • Peel JB, Sui X, Adams SA et al (2009) A prospective study of cardiorespiratory fitness and breast cancer mortality. Med Sci Sports Exerc 41(4):742–748

    Article  PubMed Central  PubMed  Google Scholar 

  • Peel AB, Thomas SM, Dittus K et al (2014) Cardiorespiratory fitness in breast cancer patients: a call for normative values. J Am Heart Assoc 3(1):e000432

    Article  PubMed Central  PubMed  Google Scholar 

  • Perez EA, Suman VJ, Davidson NE et al (2004) Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North central cancer treatment group N9831 intergroup adjuvant trial. J Clin Oncol 22(18):3700–3704 (Erratum in: (2005) J Clin Oncol 23(7):1594)

    Article  CAS  PubMed  Google Scholar 

  • Perez EA, Suman VJ, Davidson NE et al (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231–1238

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672

    Article  CAS  PubMed  Google Scholar 

  • Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808–3815

    Article  CAS  PubMed  Google Scholar 

  • Pituskin E, Haykowsky M, Mackey JR et al (2011) Rationale and design of the multidisciplinary approach to novel therapies in cardiology oncology research trial (MANTICORE 101-breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 11:318

    Article  PubMed Central  PubMed  Google Scholar 

  • Rivera CM, Grossardt BR, Rhodes DJ et al (2009) Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16(1):15–23

    Article  PubMed Central  PubMed  Google Scholar 

  • Rock CL, Flatt SW, Newman V et al (1999) Factors associated with weight gain in women after diagnosis of breast cancer. Women’s healthy eating and living study group. J Am Diet Assoc 99:1212–1221

    Article  CAS  PubMed  Google Scholar 

  • Sawaya H, Sebag IA, Plana JC et al (2011) Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107:1375–1380

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sawaya H, Sebag IA, Plana JC et al (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5(5):596–603

    Article  PubMed Central  PubMed  Google Scholar 

  • Sawyer DB (2013) Anthracyclines and heart failure. N Engl J Med 368(12):1154–1156

    Article  CAS  PubMed  Google Scholar 

  • Schonberg MA, Marcantonio ER, Ngo L et al (2011) Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol 29(12):1570–1577

    Article  PubMed Central  PubMed  Google Scholar 

  • Seidman A, Hudis C, Pierri MK et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215–1221

    Article  CAS  PubMed  Google Scholar 

  • Simonsick EM, Fan E, Fleg JL (2006) Estimating cardiorespiratory fitness in well-functioning older adults: treadmill validation of the long distance corridor walk. J Am Geriatr Soc 54(1):127–132

    Article  PubMed  Google Scholar 

  • Smith LA, Cornelius VR, Plummer CJ et al (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomized controlled trials. BMC Cancer 10:337

    Article  PubMed Central  PubMed  Google Scholar 

  • Steingart RM, Bakris GL, Chen HX et al (2012) Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 163(2):156–163

    Article  CAS  PubMed  Google Scholar 

  • Swain SM, Vici P (2004) The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 130(1):1–7

    Article  CAS  PubMed  Google Scholar 

  • Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869–2879

    Article  CAS  PubMed  Google Scholar 

  • Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31):7811–7819

    Article  CAS  PubMed  Google Scholar 

  • Valachis A, Nearchou A, Polyzos NP et al (2013) Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer 133(9):2245–2252

    Article  CAS  PubMed  Google Scholar 

  • van Dalen EC, Caron HN, Dickinson HO et al (2008) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2208(2):CD003917

    Google Scholar 

  • van de Water W, Markopoulos C, van de Velde CJ et al (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 307(6):590–597

    PubMed  Google Scholar 

  • Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 32(9):927–934

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Vejpongsa P, Yeh ET (2014) Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 95(1):45–52

    Article  CAS  PubMed  Google Scholar 

  • Wells QS, Lenihan DJ (2010) Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected? Prog Cardiovasc Dis 53(2):140–148

    Article  PubMed  Google Scholar 

  • Wojnowski L, Kulle B, Schirmer M et al (2005) NADPH oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754–3762

    Article  CAS  PubMed  Google Scholar 

  • Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147–e239

    Article  PubMed  Google Scholar 

  • Yeboah J, Rodriguez CJ, Stacey B et al (2012a) Prognosis of individuals with asymptomatic left ventricular systolic dysfunction in the multi-ethnic study of atherosclerosis (MESA). Circulation 126(23):2713–2719

    Article  PubMed Central  PubMed  Google Scholar 

  • Yeboah J, McClelland RL, Polonsky TS et al (2012b) Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 308(8):788–795

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yeh ET, Tong AT, Lenihan DJ et al (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109(25):3122–3131

    Article  PubMed  Google Scholar 

  • Yingchoncharoen T, Agarwal S, Popović ZB et al (2013) Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr 26(2):185–191

    Article  PubMed  Google Scholar 

  • Young MN, Shoemaker MB, Kurtz EG et al (2012) Heart failure with preserved left ventricular function: diagnostic and therapeutic challenges in patients with diastolic heart failure. Am J Med Sci 344(5):399–405

    PubMed  Google Scholar 

  • Zhang S, Liu X, Bawa-Khalfe T et al (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18(11):1639–1642

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Cancer Prevention and Survivorship Center, University of Kansas Cancer Center, 2330 Shawnee Mission Parkway Suite 1102, Westwood, KS, 66205, USA

    Carol Fabian M.D. (Director)

Authors
  1. Carol Fabian M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol Fabian M.D. .

Editor information

Editors and Affiliations

  1. Distinguished Professor of Health Policy & Management and Medicine, Director, Cancer Prevention & Control Research, UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA

    Patricia A. Ganz

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Breast Cancer Research Foundation

About this chapter

Cite this chapter

Fabian, C. (2015). Prevention and Treatment of Cardiac Dysfunction in Breast Cancer Survivors. In: Ganz, P. (eds) Improving Outcomes for Breast Cancer Survivors. Advances in Experimental Medicine and Biology(), vol 862. Springer, Cham. https://doi.org/10.1007/978-3-319-16366-6_14

Download citation

Publish with us

Policies and ethics

Search

Navigation